Dr. Julia Judd is a graduate of the Philadelphia College of Osteopathic Medicine and completed her residency at Temple University Hospital. She was a fellow in Hematology/Oncology at Fox Chase Cancer Center and is now a Clinical Instructor at Fox Chase Cancer Center. Her research focuses on ancestry-related survival disparities in lung cancer and is supported by the Fox Chase Ruth L. Kirschstein NRSA Institutional Research Training Grant (T32).

Alex A. Adjei is a Consultant and Professor of Oncology and Pharmacology at Mayo Clinic. He is the Director of the Early Cancer Therapeutics program. Dr Adjei’s research is focused on experimental therapeutics and clinical drug development. He received the first ASCO Drug Development Research Professorship 2012-2017, in recognition of his mentorship and his work in cancer drug development. He is also a leader in lung cancer research, and is director of the lung cancer program at Mayo Clinic. He previously served on the board of directors of the IASLC. He is currently co-chair of the Thoracic Malignancies Steering Committee, and member of the Board of Scientific Counselors of the National Cancer Institute. He is the Editor-in-Chief of the Journal of Thoracic Oncology, and JTO CRR. He received the IASLC Adi F. Gazdar Merit Award for Distinguished Service in Lung Cancer Research, in January 2021, and is the recipient of ESMO’s Lifetime Achievement Award for 2021.
Alex A. Adjei is a Consultant in Oncology, Professor of Oncology and Professor of Pharmacology at Mayo Clinic and Mayo College of Medicine, in Rochester, MN. He oversees oncology drug development as well as lung cancer research and treatment across all 3 Mayo Clinic sites, and is co-Leader of the Developmental Therapeutics program at Mayo Cancer Center.
Dr Adjei has served on a number of US National Cancer Institute (NCI) committees. From 2007 to 2013, he was Chair of the NIH Study Section NCRR Clinical Research Review Committee, reviewing CTSAs. From 2010 – 2014, he was a Member of the Clinical Oncology Study Section (CONC), and from 2013-2017, he was a member of NCI IRG Subcommittee A, reviewing Cancer Centers. He is currently co-chair of the Thoracic Malignancies Steering Committee of NCI. He has served on various committees of professional societies. He was the President of the Minorities in Cancer Research Council of AACR and a member of the Board of Directors of IASLC and is currently Faculty Coordinator for Developmental Therapeutics and member of the Gender Medicine Task Force of ESMO. Dr Adjei is serving on the Committee on Diagnosing and Treating Adult Cancers of the US National Academies of Sciences, Engineering and Medicine, tasked with providing a report on this topic to the US government (Social Security Administration). He is the Editor-in-Chief of the Journal of Thoracic Oncology and JTO Clinical and Research Report.
Dr Adjei’s research is focused on experimental therapeutics and clinical drug development. He received the first American Society of Clinical Oncology Drug Development Research Professorship 2012-2017, in recognition of his mentorship and his work in cancer drug development. He also received the inaugural IASLC Adi F. Gazdar Merit Award for Distinguished Service in Lung Cancer, in 2020. He has authored 290 publications dealing primarily with preclinical pharmacology and phase I trials as well as novel therapies for lung cancer.